SLP7111228
SLP7111228 is a selective sphingosine kinase 1 (SphK1) inhibitor and anti-inflammatory agent. SLP7111228 selectively inhibits SphK1 and reduces the production of sphingosine-1-phosphate. SLP7111228 decreases lipopolysaccharide-induced TNFα and IL-1β levels. SLP7111228 alleviates obliterative pulmonary arteriopathy, increases cardiac index and decreases total pulmonary vascular resistance index. SLP7111228 can be used in research related to neuroinflammatory diseases and pulmonary hypertension.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1449765-82-5
- Formule: C22H33N5O
- Masse moléculaire:383.53
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform TNF Receptor
More
Activité biologique
Description
IC50 & Target
[2]|
SphK1 |
IL-1β |
TNF-α |
In Vitro
SLP7111228 (1 µM; 30 min pre-incubation, 4 h LPS incubation) significantly reduces LPS-induced IL-1β mRNA expression in BV2 mouse microglia cells, with a non-significant reduction in TNFα mRNA expression[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:BV2 mouse microglia cells
-
Concentration:1 µM
-
Incubation Time:30 min (pre-incubation); 4 h (incubation with LPS)
-
Result:Significantly reduced LPS-induced IL-1β mRNA expression.
Reduced TNFα mRNA expression, but this effect was not statistically significant due to high variability between experiments.
Showed the same level of inhibition of LPS-induced TNFα and IL-1β mRNA expression as either inhibitor used alone when combined with the SphK2 inhibitor SLM6031434 (HY-120268).
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (adult male, ~250 g, Su/Hx/Nx model)[2]
-
Dosage:10 mg/kg
-
Administration:i.p.; daily; 3 weeks
-
Result:Significantly decreased plasma S1P levels without affecting sphingosine levels.
Reduced vascular occlusion in small, medium, and large pulmonary arteries.
Reduced diastolic right ventricular internal diameter (RVID) in correlation with lower S1P.
Improved cardiac index and decreased total pulmonary artery resistance index.
Does not alter right ventricular pressure, hypertrophy, systemic pressure, or heart rate.
Chemical Information
-
CAS No. 1449765-82-5
-
Masse moléculaire 383.53
-
Formule C22H33N5O
-
SMILES
CCCCCCCCC(C=C1)=CC=C1C2=NOC(C[C@H]3N(CCC3)C(N)=N)=N2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Pureté et documentation
Références
[1]. Standoli S, et al. Sphingosine Kinases at the Intersection of Pro-Inflammatory LPS and Anti-Inflammatory Endocannabinoid Signaling in BV2 Mouse Microglia Cells. Int J Mol Sci. 2023 May 9;24(10):8508. [Content Brief]
[2]. Gairhe S, et al. Sphingosine-1-phosphate is involved in the occlusive arteriopathy of pulmonary arterial hypertension. Pulm Circ. 2016;6(3):369-380. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)